4 citations
,
February 2019 in “Revista da Associação Médica Brasileira” FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.
7 citations
,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
1 citations
,
February 2018 in “Orthopedics and rheumatology” Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
July 2024 in “Journal of Investigative Dermatology” Scalp cooling may be less effective for women of color on certain chemotherapy treatments.
1 citations
,
October 2024 in “Journal of the Endocrine Society” Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
12 citations
,
July 2014 in “Journal of Investigative Dermatology” Chemotherapy causes complex changes in hair follicle cells that can lead to hair loss.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
MVP treatment is effective and safe for recurrent breast cancer.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
5 citations
,
April 2016 in “PubMed” Cetuximab often causes skin problems, but they can be managed without stopping treatment.
Melatonin may protect hair follicle stem cells from damage caused by chemotherapy.
39 citations
,
August 2022 in “Pharmaceutics” Combining letrozole and quercetin in spanlastics may improve breast cancer treatment.
8 citations
,
January 1977 in “Acta Haematologica” The treatment was effective for advanced non-Hodgkin's lymphomas.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
Minoxidil and a solvent mixture can prevent hair loss caused by chemotherapy in mice.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
April 2023 in “Journal of Investigative Dermatology” Melatonin may help prevent hair loss caused by the chemotherapy drug paclitaxel.
5 citations
,
March 2020 in “Thoracic Cancer” CT-707 is effective and safe for treating certain Chinese lung cancer patients.
11 citations
,
June 1996 in “Nutrition” Vitamin D3 may prevent hair loss from chemotherapy, but side effects and cancer cell protection are concerns.
3 citations
,
June 2011 in “Korean Journal of Clinical Oncology” The document concluded that there were no effective ways to prevent hair loss from chemotherapy but treatments were being explored.
294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
53 citations
,
October 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical calcitriol-analogs can reduce hair loss caused by chemotherapy.
January 2012 in “Chinese Clinical Oncology” Disodium folinate can safely and effectively replace calcium folinate in colorectal cancer treatment.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
November 2021 in “World Family Medicine Journal /Middle East Journal of Family Medicine” COVID-19 affects patients on chemotherapy for gynecological cancer negatively.